{"Clinical Trial ID": "NCT02953860", "Intervention": ["INTERVENTION 1:", "With enzalutamide", "500mg of Fulvant will be given on days 1, 15, 28, then every 4 weeks according to the standard of care (SOC) and 160mg of Enzalutamide will be given, in combination with Fulvant, PO per day.", "With Enzalutamide: 500mg of Fulvestrant will be given at IM on days 1, 15, 28, then every 4 weeks according to the standard of care (SOC) and 160mg of Enzalutamide will be given daily. Patients will receive tumour biopsy at the beginning of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end of treatment."], "Eligibility": ["Incorporation criteria:", "ER+ Her2- breast cancer", "Metastatic", "Women at least 18 years of age", "A candidate for treatment with fulvestrant - patients who have started treatment with fulvestrant may participate in this trial if within 3 months of the start of treatment with fulvestrant", "- Measurable or evaluable by RECIST 1.1", "- ECOG PS 0-2", "\u2022 Capable of swallowing the study drug and complying with the requirements of the study", "The tumours available for fresh biopsy (two biopsies - pretreatment for enzalutamide, and during treatment at 4 weeks) are also asked if the patient would be willing to provide a third biopsy at the time of progression.", "If the patient is pre- or peri-menopausal, then concomitant ovarian suppression is required. Patients may have already received the ovarian suppression charge dose. Pre- or peri-menopausal subjects should have a confirmed negative urine pregnancy test during screening.", "ANC > 1000/uL and platelets > 75 000/uL during screening visit", "Total bilirubin < 1.5 times the upper limit of normal (ULN) at the screening visit, unless there is another non-malignant etiology (e.g. Gilbert's disease)", "Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or < 5 times ULN if patient has documented liver metastases", "Creatinine < 1.5 times ULN", "INR < 1.5 ULN, or if on warfarin, can move safely for biopsy", "Want to give blood for the search at 4 moments", "Informed written consent obtained prior to biopsies and blood samples", "Subjects should use 2 acceptable contraceptive methods (one of which should include a condom as a barrier contraception method) from the time of screening for an enzalutamide study and continue throughout treatment and for at least three months after enzalutamide has been discontinued.", "- Exclusion criteria:", "\u2022 Current or previously treated brain or leptometinal metastases", "History of convulsions", "Previous anti-androgen therapy (abiraterone, RNA-509, bicalutamide, enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464)", "\u2022 Systemic or androgen estrogens within 14 days of starting treatment. Vaginal estrogens are allowed if necessary for patient comfort."], "Results": ["Performance measures:", "Clinical benefit rate of the combination Enzalutamide/ Fulvestrant", "\u00b7 By response Criteria for assessing solid tumours (RECIST v1.0) for target lesions assessed by scanner or caliper Full response (CR), elimination of all target lesions Partial response (PR), >=30% decrease in the sum of the longest diameter of target lesions Overall response (RO) = RC + PR; clinical benefit rate (CBR) at 24 weeks (CR + PR + stable disease of at least 24 weeks duration.", "Time limit: 24 weeks", "Results 1:", "Title of the arm/group: Fulvestrant with enzalutamide", "Description of the arm/group: 500mg of Fulvestrant will be given in IM on days 1, 15, 28, then every 4 weeks according to the standard of care (SOC) and 160mg of Enzalutamide will be given in conjunction with Fulvestrant, PO daily.", "With Enzalutamide: 500mg of Fulvestrant will be given at IM on days 1, 15, 28, then every 4 weeks according to the standard of care (SOC) and 160mg of Enzalutamide will be given daily. Patients will receive tumour biopsy at the beginning of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end of treatment.", "Total number of participants analysed: 32", "Type of measure: Number of participants", "Unit of measure: Participants 7 21.9%"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/32 (6.25 per cent)", "Myocardial infarction [1]1/32 (3.13 per cent)", "Cholecystitis [2]1/32 (3.13%)"]}